Related Experiment Video
Updated: Jun 14, 2026
10:33
Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
Diffuse unilateral subacute neuroretinitis in the United Kingdom
Evelyne Oueghlani1, Eoin O'Sullivan, Carlos E Pavesio
1Moorfields Eye Hospital, 162 City Road, London, EC1V 2PD, UK. oueghla_eve@hotmail.com
International Ophthalmology
|March 26, 2010
Summary
The first UK cases of diffuse unilateral subacute neuroretinitis (DUSN) were successfully treated with albendazole. This medication effectively restored vision and resolved retinal lesions, offering a safe alternative when worms are not visible.
Area of Science:
- Ophthalmology
- Infectious Diseases
Background:
- Diffuse unilateral subacute neuroretinitis (DUSN) is a rare inflammatory eye condition.
- Early diagnosis and treatment are crucial for preserving vision in DUSN patients.
Observation:
- Two UK patients presented with unilateral vision loss and characteristic retinal lesions.
- Retinal lesions in DUSN were observed to migrate over several weeks.
- No subretinal worm was visualized in either patient, complicating traditional diagnosis.
Findings:
- Both patients received oral albendazole (400 mg daily for 30 days).
- Within 4 weeks, vision improved to 6/9 in both patients.
- Complete resolution of retinal lesions and sustained vision were noted during long-term follow-up.
Implications:
- Oral albendazole is a safe and effective treatment for DUSN, especially when laser photocoagulation is not feasible.
- This study highlights albendazole as a viable therapeutic option for DUSN in the UK.
- Prompt treatment with albendazole can prevent vision loss associated with DUSN.
